Business Wire

1PASSWORD

4.6.2024 07:01:32 CEST | Business Wire | Press release

Share
1Password Strengthens EMEA Presence with Significant Business Growth, Key Customer Wins, and Region-Specific Product Capabilities

1Password, a leader in identity security, today announced significant business momentum across Europe, the Middle East, and Africa (EMEA). With a strategic focus on the region, 1Password is expanding its workforce, launching products tailored to the EMEA market, and securing over 35% of Europe’s Top 100 companies. Today, over one-third of 1Password’s B2B customers are based in EMEA.

The majority (68%) of security breaches are still caused by a human element resulting in compromised credentials, and the company recently launched 1Password Extended Access Management (XAM), an industry-first solution designed to secure every login to every app from every device, addressing the modern workforce’s need for even more seamless and secure access. Now available in the EMEA region, this solution protects users' privacy and gives businesses strong security across managed and unmanaged applications and devices, while offering visibility and insights to help them meet resilience, compliance, and audit goals. As a leading enterprise password manager, 1Password enhances identity security by providing businesses with secure access to their most sensitive information, such as login credentials and SSH keys, actionable insights to address vulnerabilities, and seamless integration with existing security infrastructure.

1Password recently hired Oliver Cheal as Vice President, EMEA. In this role, he will oversee the company’s EMEA-based teams that are focused on designing, developing, selling, and supporting 1Password’s identity and access management solutions for customers in the region. Cheal was most recently at Cisco and Duo Security and his background is in transforming cybersecurity businesses by leading organizational change and building out the go-to-market function. With more than 100 employees in EMEA, 1Password is actively investing in its EMEA workforce, with plans to open positions across sales, marketing, customer success, and partnerships in the UK, Netherlands, and Germany.

“I am thrilled to join 1Password at such a pivotal time and grow our EMEA team to better serve our customers across the region,” said Oliver Cheal, VP of EMEA. “With 1Password Extended Access Management, we're revolutionizing access management by bridging the gaps left by traditional IAM solutions. With its seamless integration and user-friendly design, we are able to empower IT and security teams with unparalleled visibility and control, ensuring their employees can safely use the tools they need, whether working remotely or in the office.”

Earlier this year, the company launched the 1Password Global Partner Program and the 1Password® Enterprise Password Manager - MSP Edition in beta to provide resellers, distributors, and Managed Service Providers (MSPs) with the tools and resources they need to help their customers become more secure. Key strategic partners in EMEA include Amazon Web Services (AWS), Arrow Electronics, Insight Enterprises, Tap.De, and SVA.

“Watching 1Password's expansion into EMEA is incredibly exciting. Their growth and vision have always perfectly aligned with ours, and we are thrilled to be part of this journey, supporting their success every step of the way. By addressing critical security gaps with their new Extended Access Management (XAM) solution, 1Password is pioneering a new category in cybersecurity that ensures comprehensive protection across the modern, hybrid work environment and we are excited to be their partner,” said Ikramul Khaled, the Group Head of Vendor Alliances at QBS Technology Group.

For more information about 1Password, visit our website here.

About 1Password

Trusted by over 150,000 businesses and millions of consumers, 1Password offers identity security and access management solutions built for the way people work and live today. 1Password is on a mission to eliminate the conflict between security and productivity while securing every sign-in for every app on every device. As the provider of the most-used enterprise password manager, 1Password continues to innovate on its strong foundation to offer security solutions relied upon by companies of all sizes, including Associated Press, Salesforce, GitLab, Under Armour, and Intercom.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240603036115/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye